Update shared on05 Oct 2025
Fair value Increased 15%Analysts have raised their price target for Bioventus from $12.75 to approximately $14.67 per share, citing improvements in projected revenue growth and a more favorable future price-to-earnings outlook.
What's in the News
- Bioventus issued new earnings guidance for 2025 and estimates net sales between $560 million and $570 million. (Company Guidance)
- The company received FDA 510(k) clearance for both TalisMann and StimTrial devices, expanding its portfolio of Peripheral Nerve Stimulation (PNS) solutions for chronic pain management. (Company Announcement)
- With the FDA clearances, Bioventus now offers a comprehensive PNS portfolio. This enables physicians to potentially treat a broader spectrum of patients from initial assessment to long-term therapy. (Company Announcement)
- The PNS market is estimated to be growing above 20 percent annually and could exceed $500 million by 2029. This positions Bioventus for substantial growth. (Company Announcement)
Valuation Changes
- Consensus Analyst Price Target increased from $12.75 to approximately $14.67 per share, reflecting a notable upward revision.
- Discount Rate improved slightly as it declined from 9.14 percent to 9.05 percent.
- Revenue Growth expectations rose modestly from 5.07 percent to 5.41 percent.
- Net Profit Margin saw a slight decrease, moving from 11.29 percent to 11.18 percent.
- Future P/E multiple has increased from 15.93x to 18.28x, indicating a higher anticipated valuation.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.